ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

AGRX Agile Therapeutics Inc

0.6022
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Agile Therapeutics Inc NASDAQ:AGRX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.6022 0.27 0.2994 0 01:00:00

Agile Therapeutics to Present at the RBC Capital Markets 2017 Global Healthcare Conference

14/02/2017 9:00pm

GlobeNewswire Inc.


Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Agile Therapeutics Charts.

Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company, announced today that its Chief Executive Officer, Al Altomari will present at the RBC Capital Markets 2017 Global Healthcare Conference on February 23, 2017 at 10:00 AM ET at the New York Palace in New York City.

To access the live and archived webcasts of the presentation, visit the Investor Relations section of Agile Therapeutics website at www.agiletherapeutics.com.  The webcast will be archived on Agile Therapeutics website for 60 days following the event.

About Agile TherapeuticsAgile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method.  Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch that recently completed Phase 3 trials. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. For more information, please visit the company website at www.agiletherapeutics.com.

Contact:  Mary Coleman 609-683-1880

1 Year Agile Therapeutics Chart

1 Year Agile Therapeutics Chart

1 Month Agile Therapeutics Chart

1 Month Agile Therapeutics Chart

Your Recent History

Delayed Upgrade Clock